Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR)

Blood

Volumn 87, Issue 10, 1996, Pages 4333-4339

  Puri, Raj K ^a   Leland, Pamela ^b   Obiri, Nicholas I ^b   Husain, S Rafat ^b   Kreitman, Robert J ^b   Haas, Gabriel P ^b   Pastan, Ira ^b   Debinski, Waldemar ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 13; INTERLEUKIN 13 PE38QQR; PSEUDOMONAS EXOTOXIN A; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING SITE; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN SYNTHESIS INHIBITION;

EID: 0029934957     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.10.4333.bloodjournal87104333     Document Type: Article

References (32)

1. Minty A, Chalon P, Deroq J-M, Dumont X, Guillemot J-C, Kaghad M, Labit C, Leplatois P, Liauzun P, Miloux B, Minty C, Casellas P, Loison G, Lupker J, Shire D, Ferrara P, Caput D: Interleukin 13 is a new lymphokine regulating inflammatory and immune responses. Nature 362:248, 1993
2. Michel G, Ried C, Beetz A, Kemeny L, Ruzicka T: IL-6 is a potent inducer of IL-13 mRNA in normal human keratinocytes. J. Invest. Dermatology 103:433, 1994
3. McKenzie ANJ, Culpepper JA, de waal Malefyt R, Briers F, Punnonen J, Aversa G, Sato A, Dang W, Cocks BG, Menon S, de Vries JE, Zurawski G: Interleukin 13, a T-cell-derived cytokine that regulates human monocytes and B-cell function. Proc Natl Acad Sci USA 90:3735, 1993
4. Morgan JG, Dolganov GM, Robbins SE, Hinton LM, Lovett M: The selective isolation of novel cDNA encoded by the regions surrounding the human interleukin-4 and 5 genes. Nucleic Acids Res 20:5173, 1992
5. Zurawski G, de Vries JE: Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today 15:19, 1994
6. Punnonen J, Aversa G, Cocks BG, Mckenzie ANJ, Menon S, Zurawski G, de Waal Malefyt R, de Vries JE: Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc Natl Acad Sci USA 90:3730, 1993
7. de Waal Malefyt R, Figdor CG, Huijbens R, Mohan-Peterson S, Bennet B, Culpepper J, Dang W, Zurawski G, de Vries JE: Effects of IL-13 on phenotype, cytokine production, and cytokine function of human monocytes. Comparison with IL-4 and modulation by IFN-g or IL-10. J Immunol 151:6370, 1993
8. de Waal Malefyt R, Figdor CG, de Vries JE: Effects of interleukin-4 on monocyte functions: Comparison to interleukin-13. Res Immunol 144:629, 1993
9. Cocks BG, de Waal Malefyt R, Galizzi J-P, de Vries JE: IL-13 induces proliferation and differentiation of human B cells activated by the CD40 ligand. Int Immunol 5:657, 1993
10. Defrance T, Carayon P, Billian G, Guillemot JC, Minty A, Caput D, Ferrara P: Interleukin 13 is a B cell stimulating factor. J Exp Med 179:1325, 1994
11. Punnonen J, de Vries J: IL-13 induces proliferation, Ig isotype switching and Ig synthesis by immature fetal B cells. J Immunol 152:1094, 1994
12. Aversa G, Punnonen J, Cocks BG, de Waal Malefyt R, Vega F, Surawski SM, Zurawski G, de Vries JE: An interleukin 4 mutant protein inhibits both IL-4 and IL-13 induced human immunoglobulin G4 (IgG4) and IgE synthesis and B cell proliferation: Support for a common component shared by IL-4 and IL-13 receptors. J Exp Med 178:2213, 1993
13. Obiri NI, Debinski W, Leonard WJ, Puri RK: Receptor for interleukin 13: Interaction with interleukin 4 by a mechanism that does not involve the common γ chain shared by receptors for interleukin 2, 4, 7, 9, and 15. J Biol Chem 270:8797, 1995
14. Obiri NI, Puri RK: Characterization of interleukin-4 receptors expressed on human renal cell carcinoma cells. Oncol Res 6:419, 1994
15. Pastan I, FitzGerald D: Recombinant toxins for cancer treatment. Science 254:1173, 1991
16. Debinski W, Obiri NI, Pastan I, Puri RK: A novel chimeric protein composed of IL-13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for IL-13 and IL-4. J Biol Chem 270:16775, 1995
17. Pastan I, Chaudahry VK, FitzGerald DJ: Recombinant toxins as novel therapeutic agents. Annu Rev Biochem 61:331, 1992
18. Debinski W, Pastan I: An immunotoxin with increased activity and homogeneity produced by reducing the number of lysine residues in recombinant Pseudomonas exotoxin. Bioconjugate Chem 5:40, 1994
19. Obiri NI, Hillman G, Haas GP, Sud S, Puri RK: Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. J Clin Invest 91:88, 1993
20. Puri RK, Ogata M, Leland P, Feldman GM, Pastan I: Expression of high affinity IL-4 receptors on murine sarcoma cells and receptor mediated cytotoxicity of tumor cells to chimeric protein between IL-4 and Pseudomonas exotoxin. Cancer Res 51:3011, 1991
21. Lowenthal JW, Castle BE, Christian J, Schreurs J, Rennick D, Arai N, Hoy P, Takebe Y, Howard M: Expression of high affinity receptors for murine interleukin 4 (BSF-1) on hematopoietic and nonhematopoietic cells. J Immunol 140:456, 1988
22. Jacobsen SEW, Okkenhaug C, Veiby OP, Caput D, Ferrara P, Minty A: Interleukin-13: Novel role in direct regulation of proliferation and differentiation of primitive hematopoietic progenitor cells. J Exp Med 180:75, 1994
23. Puri RK, Debinski W, Obiri N, Kreitman R, Pastan I: Human renal cell carcinoma cells sensitive to the cytotoxic effect of a chimeric protein composed of human interleukin-4 and Pseudomonas exotoxin. Cell Immunol 154:369, 1994
24. Loberboum-Galski H, Kozak RW, Waldman TA, Bailon P, FitzGerald DP, Pastan I: Interleukin-2 (IL-2) PE40 is cytotoxic to cells displaying either the p55 or p70 subunit of the IL-2 receptor. J Biol Chem 263:18650, 1988
25. Siegall CB, Xu Y-H, Chaudhary VK, Adhya S, FitzGerald D, Pastan I: Cytotoxic activities of a fusion protein comprised of TGFα and Pseudomonas exotoxin. FASEB J 3:2647, 1989
26. Puri RK, Leland P, Kreitman RJ, Pastan I: Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the cytotoxic effect of IL4-Pseudomonas exotoxin chimeric protein. Int J Cancer 58:574, 1994
27. Kreitman RJ, Puri RK, Pastan I: A circularly permutated recombinant interleukin-4 toxin with increased activity. Proc Natl Acad Sci USA 91:6889, 1994
28. Kreitman RJ, Puri RK, Pastan I: Increased antitumor activity of a circularly permuted IL4-toxin in mice with IL-4 receptor bearing human carcinoma. Cancer Res 55:3357, 1995
29. Le HV, Seelig GF, Syto R, Ramanathan L, Winder WT, Borkowski D, Trotta PP: Selective proteolytic cleavage of recombinant human interleukin-4. Evidence for a critical role of the C-terminus. Biochemistry 30:9576, 1991
30. Ramanathan L, Ingram R, Sullivan L, Greenberg R, Reim R, Trotta PP, Le HV: Immunochemical mapping of domains in human interleukin 4 recognized by neutralizing monoclonal antibodies. Biochemistry 32:3549, 1993
31. Morrison B, Leder P: A receptor binding domain of mouse interleukin-4 defined by a solid phase binding assays and in vitro mutagenesis. J Biol Chem 267:11957, 1992
32. c chain in RCC cells does not improve sensitivity. Cell Immunol (in press)